Expected Next-Generation Drugs Under Development in Relation to Voiding Symptoms

키워드

참고문헌 (34)

1. Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review, "Brasure M", Agency for Healthcare Research and Quality (US), ~ (2016)
2. Roehrborn CG, "Benign prostatic hyperplasia: an overview", Rev Urol, 7(Suppl 9), pp.S3~S14 (2005)
3. Dahm P, "Comparative effectiveness of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia : a systematic review and meta-analysis", Eur Urol, 71, pp.570~581 (2017)
4. "Benign prostatic hyperplasia treatment market value to reach nearly $5 billion" (2017)[URL]
5. Abrams P, "The standardisation of terminology of lower urinary tract function : report from the Standardisation Sub-committee of the International Continence Society", Neurourol Urodyn, 21, pp.167~178 (2002)
6. "Drug firms helped create $3 billion overactive bladder market" (2016)[URL]
7. Hashim H, "Emerging drugs for the treatment of benign prostatic obstruction", Expert Opin Emerg Drugs, 15, pp.159~174 (2010)
8. Kunit T, "An evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia", Res Rep Urol, 6, pp.67~70 (2014)
9. Fadok VA, "Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages", J Immunol, 148, pp.2207~2216 (1992)
10. Magistro G, "New intraprostatic injectables and prostatic urethral lift for male LUTS", Nat Rev Urol, 12, pp.461~471 (2015)
11. Elhilali MM, "Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia", J Urol, 189, pp.1421~1426 (2013)
12. Ezzati M, "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain", Womens Health (Lond), 11, pp.19~28 (2015)
13. Diamond MP, "Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study", Reprod Sci, 21, pp.363~371 (2014)
14. Uckert S, "Phosphodiesterase(PDE)inhibitors in the treatment of lower urinary tract dysfunction", Br J Clin Pharmacol, 72, pp.197~204 (2011)
15. 김용웅, "Inhibitory Effects of Isoflavonoids on Rat Prostate Testosterone 5α-Reductase", Journal of Acupuncture & Meridian Studies, 5(6), pp.319~322 (2012), 사단법인약침학회[DOI]
16. Lee J, "Pharmacokinetics, safety and tolerability of DA-6034, an anti-inflammatory agent, after single and multiple oral administrations in healthy volunteers", Clin Drug Investig, 34, pp.37~42 (2014)
17. Pharma F., "Global benign prostatic hyperplasia market and competitive landscape highlights–2016" (2016), Research and Markets
18. Salcedo C, "In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder", Br J Pharmacol, 156, pp.807~817 (2009)
19. Song M, "The efficacy and tolerability of tarafenacin, a new muscarinic acetylcholine receptor M3 antagonist in patients with overactive bladder; randomised, double-blind, placebo-controlled phase 2 study", Int J Clin Pract, 69, pp.242~250 (2015)
20. Thiagamoorthy G, "Current and future pharmacotherapy for treating overactive bladder", Expert Opin Pharmacother, 17, pp.1317~1325 (2016)
21. Dmochowski RR, "Clinical safety, tolerability and efficacy of combination tolterodine", pilocarpine in patients with overactive bladder, 2014, pp.68, 986~994
22. Zacche MM, "Phase II drugs that target cholinergic receptors for the treatment of overactive bladder", Expert Opin Investig Drugs, 23, pp.1365~1374 (2014)
23. Ellsworth P, "Treatment of overactive bladder symptoms beyond antimuscarinics : current and future therapies", Postgrad Med, 124, pp.16~27 (2012)
24. Biers SM, "The effects of a new selective beta3-adrenoceptor agonist(GW427353)on spontaneous activity and detrusor relaxation in human bladder", BJU Int, 98, pp.1310~1314 (2006)
25. Karl-Erik Andersson, "Drug therapy of overactive bladder - What is coming next?", Investigative and Clinical Urology, 56(10), pp.673~679 (2015), 대한비뇨기과학회[DOI]
26. Abrams P, "Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)", Eur Urol, 67, pp.577~588 (2015)
27. Morelli A, "The vitamin D receptor agonist elocalcitol upregulates L-type calcium channel activity in human and rat bladder", Am J Physiol Cell Physiol, 294, pp.C1206~C1214 (2008)
28. Digesu GA, "Phase IIb, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine effects of elocalcitol in women with overactive bladder and idiopathic detrusor overactivity", Urology, 80, pp.48~54 (2012)
29. Leite VF, "Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis", Pain Physician, 17, pp.E45~E60 (2014)
30. Atobe M, "Discovery of 2-(1H-indazol-1-yl)-thiazole derivatives as selective EP(1)receptor antagonists for treatment of overactive bladder by core structure replacement", Bioorg Med Chem Lett, 24, pp.1327~1333 (2014)
31. Chapple CR, "Phase II study on the efficacy and safety of the EP1receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome", J Urol, 191, pp.253~260 (2014)
32. Petkov GV, "Role of potassium ion channels in detrusor smooth muscle function and dysfunction", Nat Rev Urol, 9, pp.30~40 (2011)
33. Ruggieri MR Sr., "Cannabinoids: potential targets for bladder dysfunction", Handb Exp Pharmacol, (202), pp.425~451 (2011)
34. Andersson KE, "The role of the transient receptor potential(TRP)superfamily of cation-selective channels in the management of the overactive bladder", BJU Int, 106, pp.1114~1127 (2010)

관련 논문AI추천